DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced regulatory approval in Australia for three of its Impella products. The Australian Register of Therapeutic Goods (ARTG) has approved the sale of Abiomed’s Impella LP 2.5 percutaneous left ventricular assist device, Impella LP 5.0 and Impella LD. The technology will be distributed in Australia through the distributor N. Stenning & Co. Pty. Ltd., Abiomed’s distributor for the AB5000 and BVS 5000 Circulatory Support Systems.
